David is the Chief Medical Officer at Norgine and has been in post since May 2022.  David qualified in Medicine, Physiology and Clinical Pharmacology from St. Mary’s Hospital (Imperial College of Science, Technology and Medicine) in 1992. He retained this interest in Pharmaceutical Medicine during his postgraduate training in Cardiology and General Medicine and joined Pfizer Global Research and Development in Sandwich in 1999. At Pfizer, David worked in Clinical Development and in Medical Affairs in the UK and also spent time working at a Global level in New York for 4 years. He rejoined Pfizer UK in April 2007 as UK Medical Director. Prior to leaving Pfizer, David was Vice President for Medical Affairs in Pfizer’s Primary Care Business Unit covering Europe, Canada, Australia and New Zealand where he established a Regional Medical Affairs group covering Pfizer’s primary care portfolio of medicines.

After leaving Pfizer David held the role of Head of International Medical Affairs for Gilead Sciences.  In this role he managed and led a group of Medical Directors across Europe and Asia – Pacific. In 2011 he then moved to work at Celgene where he was Head of Drug Safety and Risk Management for EMEA / APAC for Celgene Ltd. In addition David acted as the QPPV for Celgene’s Pharmacovigilance System in Europe. In 2016 David moved to become Vice President of International Medical Affairs at Vertex. In 2019,  he was given additional responsibility looking after the whole International Global Development and Medical function for Vertex.

Outside Industry David continues to active in the UK Clinical Research community for some time. He represented Industry on the 2010 Academy of Medical Sciences Rawlin’s review looking into UK Clinical Research competitiveness and Governance.  Beyond Clinical Research, David has served on the Innovation sub- committee of the ABPI (Initiating the ABPI Real – World data project), represents Industry on the NICE Appeal Panel was a member of the 2009 RCP working party looking at the relationship between Industry, Academic Medicine and the NHS.  David is a visiting Lecturer at Queens University Belfast and Kings College London.

Zhen is a pharmacist by background being in the pharmaceutical industry over 15 years. She has worked in many different medical functional and medical affairs roles covering country, regional and international roles and she has worked in different medicines categories from consumer, medical devices to pharmaceutical medicines. In recent years she has been focused on rare diseases and working on pre-launch and launch. In late 2024, she moved to a commercial role as Head of DEE & Epilepsy at UCB.

Following her graduation as Doctor in Veterinary Medicine and her specialization in tropical medicine at the Universite de Liege (Belgium), Pamela practiced as a veterinarian in zoos and several small animal practices.

She then began her career in the industry in Clinical Research as Clinical Research Associate then Program Manager in a contract research organization.

After leading the Scientific Communication at Mars/Royal Canin for Belgium and Luxemburg, she joined Takeda 10 years ago and has since held several positions in Medical Affairs at country, regional and global level. She is currently Global Medical Excellence Lead and takes care of developing and implementing Medical Affairs processes and capability building initiatives for the Medical colleagues across the organization, mainly around Insights Generation and Evidence Generation.
Throughout her industry career, Pamela mainly covered specialty care areas, e.g. Oncology and Immunology (GI).

Ron Weathermon, PharmD, is a seasoned Medical Affairs leader with more than 25 years of experience spanning global, regional, and local roles in the pharmaceutical industry. As Head of Innovation and Scientific Excellence at Teva Global Medical Affairs, he drives the development of forward-looking medical strategies, fosters cross-functional collaboration, and champions scientific innovation and governance across the organization. Prior to joining Teva, Ron served as Global Head of Medical Affairs Governance at Novartis, where he led large-scale organizational transformations, established a global governance framework, and expanded medical field capabilities. Recognized for his ability to align scientific excellence with business strategy, he has built and developed high-performing teams, enhanced medical compliance systems, and integrated medical functions across diverse therapeutic areas—advancing both innovation and operational rigor.

Emma is currently the Head of Global Digital Health Technology Innovation at Amgen. In her capacity she is overseeing medical excellence and the digital transformation across the organization, focusing on new ways of working through streamlining process, delivering new/enhanced systems and driving capability build and engagement.